Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3752W HIGH $17.10
Volume
2.77 M
Value Traded
1.18 M
Short % Float
1.16%
Days to Cover
1.0
-84.76%Week
-89.49%1 Month
-92.66%3 Month
-96.49%6 Month
-98.63%5 Year
-99.66%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.15 M
EPS (TTM)
-5.06
P/E Ratio
-
Ent. Value
56.96 M
Total Shares
77.28 M
Float Shares
65.38 M
Insiders
21.04%
Institutions
13.28%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
CLSD Catalyst Timeline
Dated clinical, regulatory and corporate events for Clearside Biomedical, Inc.
Past FDA Catalysts and PDUFA Decisions
How CLSD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-02-12 | CLS-AX (axitinib injectable suspension) | Phase 2b data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CLS-AX Small moleculeCompletedNCT04626128 | Neovascular Age-related Macular Degeneration | Phase 2 | COMPLETED | 87 | Oct 13, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every CLSD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CLS-AX | neovascular age-related macular degeneration | Phase 1/2a/2b | 2025-06-17 | well tolerated and demonstrated a positive safety profileRead More | Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Thorp ClayDirector | Buy | 15,000 176,141 held | $0.92 | 02/24/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in CLSD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.2 % (-50 %) | 10.47 M | 3.81 M | -9.53% ( -400.75 K) |
Ownership Trends
CLSD Short Interest
Shares sold short, counted twice a month.
1.16%
Short % of Float
of tradable shares sold short
757.2K
Shares Sold Short
+437.0% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
1.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CLSD ranks across every disease it competes in
Competitive Position is a premium feature
See how CLSD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCLSD News
About Clearside Biomedical, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next CLSD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime